Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05971862 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04934514 |
| Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors |
| unknown |
| Phase 1 / Phase 2 |
| 97 |
| SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY |
| 1 |
| Feb 20, 2024 |
| clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
| NCT05367232 | A Study of ICP-033 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06240767 | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05291182 | A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06037317 | A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors | unknown | Phase 1 | 38 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06232863 | A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer | unknown | Phase 1 | 24 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05150405 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 54 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05576961 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | unknown | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05388487 | Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors | unknown | Phase 1 | 54 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05164458 | Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies | unknown | Phase 1 | 320 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04987112 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | unknown | Phase 1 | 36 | CanWell Pharma Inc.INDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06166472 | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor | unknown | Phase 1 | 72 | AkesoINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | unknown | Phase 1 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05886868 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 2 | Nov 29, 2023 | clinicaltrials |
| NCT04190823 | A Study of RC98 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 63 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04894825 | Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China | unknown | Phase 1 | 152 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05101265 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | unknown | Phase 1 | 24 | PharmaMarINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05681000 | Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors | unknown | Phase 1 | 28 | Biostar Pharma, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06116240 | A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors | unknown | Phase 1 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06011291 | A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer | unknown | Phase 1 | 73 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05716919 | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule | unknown | Phase 1 | 32 | Machaon Biotherapeutics, Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092268 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 270 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT03129139 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors(Minnelide 101) | unknown | Phase 1 | 66 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05263180 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | unknown | Phase 1 | 30 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Oct 18, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078670 | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 96 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06078800 | A Study of YL-17231 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT05267899 | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 24 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06054932 | Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors | unknown | Phase 1 | 18 | Beijing Likang Life Science and Tech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06047431 | A Study of QL1706H in Patients With Advanced Solid Tumors | unknown | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06041035 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06008366 | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 281 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06008379 | A Study of 7MW3711 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 164 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06027346 | A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours | unknown | Phase 1 | 60 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2024source: clinicaltrials